ABBOTT LABORATORIES (ABT)
Sector: Health Care
2026 Annual Meeting Analysis
ABBOTT LABORATORIES · Meeting: April 24, 2026
Directors FOR
12
Directors AGAINST
0
Say on Pay
FOR
Auditor
FOR
Director Elections
Election of 12 Director Nominees
Dr. Ahuja joined the board in December 2025, well within the 24-month exemption window, so no TSR trigger applies; her deep medical science and healthcare leadership credentials are directly relevant to Abbott's business.
Abbott's 3-year total shareholder return outperforms the peer group median by +5.4 percentage points, far below the 35-point underperformance threshold needed to trigger a negative vote; Ms. Babineaux-Fontenot brings strong financial and governance expertise from her Walmart CFO roles.
No TSR underperformance trigger fires against the company's disclosed peer group; Dr. Blount's long tenure (since 2011) is accompanied by strong business strategy and governance credentials from her academic and nonprofit leadership roles.
As Chairman and CEO, Mr. Ford is subject to the same TSR trigger as other directors, but Abbott's 3-year return exceeds the peer group median by +5.4 percentage points, well short of the 35-point threshold; his deep operational knowledge of Abbott's global businesses supports a FOR vote.
No TSR underperformance trigger applies; Ms. Gonzalez contributes meaningful financial planning and treasury expertise from her senior finance roles at The Clorox Company, which is directly relevant to Abbott's audit and governance oversight needs.
Abbott's relative TSR is comfortably above the peer underperformance threshold; Ms. Kumbier holds two additional public company board seats (Teledyne Technologies and Ryerson Holding), which does not exceed the four-board overboarding limit, so no flags are triggered.
No TSR underperformance trigger fires; General McDew holds two additional public company board seats (Parsons Corporation and GE Aerospace) as a non-CEO non-executive director, which is within the four-board limit, and his risk management and logistics expertise is relevant to Abbott's operations.
Abbott's 3-year TSR beats the peer group median, so no underperformance trigger applies; Ms. McKinstry serves on two additional public company boards (Accenture and Mondelēz) and is the designated audit committee financial expert, satisfying all independence and financial expertise requirements.
Mr. O'Grady joined in 2023 and is a sitting public-company CEO (Northern Trust Corporation); as a sitting CEO he may hold no more than one outside public board seat, and Abbott is his only outside directorship, so the overboarding policy is satisfied and no TSR trigger applies.
No TSR underperformance trigger applies; Mr. Roman holds one additional public company board seat (Waystar Holding Corp.), well within limits, and brings extensive manufacturing and multinational operating experience as the former CEO of 3M.
Abbott's strong relative TSR means the underperformance threshold is not breached; Mr. Starks' deep medical device industry expertise — including his tenure as CEO of St. Jude Medical — is highly relevant to Abbott's core business.
No TSR underperformance trigger fires; Mr. Stratton holds one additional public company board seat (General Dynamics Corporation), within the permitted limit, and brings valuable technology and risk management expertise from his Verizon and Frontier Communications leadership roles.
All 12 director nominees receive a FOR vote. Abbott's 3-year total shareholder return of approximately +10.6% exceeds the company's disclosed compensation peer group median by +5.4 percentage points, far below the 35-percentage-point underperformance threshold required to trigger a negative director vote. No director is overboarded under the policy, attendance was strong (average 98% in 2025), all committee members are independent, and the board discloses a skills matrix and clear qualifications for each nominee.
Say on Pay
✓ FORCEO
Robert B. Ford
Total Comp
$23,173,052
Prior Support
~91% average over past six years%
Abbott's CEO received total compensation of approximately $23.2 million, which is within a reasonable range for a CEO of a highly diversified, $179 billion market-cap healthcare and medical device company; roughly 86% of total pay is performance-based (annual bonuses, stock options, and performance-based restricted shares that only vest if a minimum return-on-equity target is met), well exceeding the 50-60% variable pay threshold required by policy. Abbott's 3-year total shareholder return of approximately +10.6% outperforms the company's disclosed peer group median by +5.4 percentage points, meaning above-benchmark incentive pay is supported by shareholder outcomes rather than contradicted by them. The company has a robust Dodd-Frank-compliant clawback policy, strong share ownership requirements, no guaranteed bonuses, no employment contracts, and has consistently received well above 70% shareholder support on say-on-pay votes, with no remediation concerns.
Auditor Ratification
✓ FORAuditor
Ernst & Young LLP
Tenure
12 yrs
Audit Fees
$31,856,000
Non-Audit Fees
$7,724,000
Ernst & Young has served as Abbott's auditor since 2014 — approximately 12 years — which is well below the 25-year tenure threshold that would raise independence concerns. Non-audit fees (tax fees of $5,767,000 plus all other fees of $293,000, totaling $7,724,000, excluding audit-related fees which are more closely tied to the audit scope) represent about 24% of audit fees of $31,856,000, comfortably below the 50% threshold. No material financial restatements are disclosed, and Ernst & Young is a Big 4 firm appropriate for a company of Abbott's size and complexity.
Overall Assessment
Abbott's 2026 annual meeting ballot is straightforward and governance-friendly: all 12 director nominees earn a FOR vote given strong relative total shareholder returns, no overboarding issues, and robust board independence; the auditor ratification and say-on-pay proposals both clear all policy thresholds comfortably, supported by a 12-year auditor tenure well below the 25-year concern level and an executive pay program where 86% of compensation is performance-based and tied to shareholder returns that exceed the peer group median. The two remaining proposals — the 2026 Incentive Stock Program and the Non-U.S. Employee Stock Purchase Plan — are equity plan approvals not yet covered by this policy and are therefore noted without a vote determination.
Compensation Peer Group
19 companies disclosed in 2026 proxy filing